Endocannabinoid System and Neurodegenerative Disorders

Guest Editors:

Dr. Marco Colizzi
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

Dr. Gennaro Pagano
F. Hoffmann-La Roche AG, 4070 Basel, Switzerland

Deadline for manuscript submissions:
closed (1 April 2022)

Message from the Guest Editors

Over the years, there have been remarkable advancements in our understanding of the neurobiological underpinnings of neurodegeneration. However, despite tremendous progresses in the field, the translation of promising disease models and treatment options to the clinic of neurodegenerative disorders has thus far been modest, calling into question the difficulty of modeling normal and pathological processes occurring with aging.

Under this perspective, it is imperative to study the effects that targeting the endocannabinoid system may have for the pathogenesis of common neurodegenerative processes, including, but not limited to, oxidative stress, neuroinflammation, and glutamatergic imbalance. Preclinical and clinical studies investigating the endocannabinoid system in the etiology, brain processes and multifaceted behavioral phenotypes associated with neurodegenerative disorders are solicited for this Special Issue. Reviews providing an analytical perspective of the existing literature on the "Endocannabinoid System and Neurodegenerative Disorders" are also welcome.

mdpi.com/si/98784

Special Issue

brain sciences

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, CAPlus / SciFinder, and other databases.
Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

Contact Us